688176 亚虹医药-U
已收盘 10-16 15:00:00
资讯
新帖
简况
亚虹医药（688176）披露2026年员工持股计划草案，10月13日股价下跌0.38%
证券之星 · 10-13
亚虹医药（688176）披露2026年员工持股计划草案，10月13日股价下跌0.38%
亚虹医药（688176）10月9日主力资金净买入936.84万元
证券之星 · 10-10
亚虹医药（688176）10月9日主力资金净买入936.84万元
亚虹医药（688176）披露与Theramex签署独家授权许可协议，10月8日股价下跌11.37%
证券之星 · 10-08
亚虹医药（688176）披露与Theramex签署独家授权许可协议，10月8日股价下跌11.37%
亚虹医药(688176.SH)：与Theramex公司签署独家授权许可协议
智通财经 · 10-07
亚虹医药(688176.SH)：与Theramex公司签署独家授权许可协议
亚虹医药(688176.SH)拟推2026年员工持股计划
智通财经 · 09-29
亚虹医药(688176.SH)拟推2026年员工持股计划
亚虹医药（688176）披露APL-2501完成I期临床试验首例受试者入组公告，9月22日股价上涨1.29%
证券之星 · 09-22
亚虹医药（688176）披露APL-2501完成I期临床试验首例受试者入组公告，9月22日股价上涨1.29%
亚虹医药(688176.SH)：APL-2501完成I期临床试验首例受试者入组
智通财经 · 09-22
亚虹医药(688176.SH)：APL-2501完成I期临床试验首例受试者入组
每周股票复盘：亚虹医药（688176）将参加科创板业绩说明会
证券之星 · 09-13
每周股票复盘：亚虹医药（688176）将参加科创板业绩说明会
亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%
证券之星 · 09-09
亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%
亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%
证券之星 · 08-31
亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%
亚虹医药（688176）2026年中报简析：增收不增利
证券之星 · 08-30
亚虹医药（688176）2026年中报简析：增收不增利
每周股票复盘：亚虹医药（688176）Q2收入增21.89%
证券之星 · 08-30
每周股票复盘：亚虹医药（688176）Q2收入增21.89%
亚虹医药（688176）披露APLD-2304获得欧盟CE认证，8月28日股价下跌0.5%
证券之星 · 08-28
亚虹医药（688176）披露APLD-2304获得欧盟CE认证，8月28日股价下跌0.5%
亚虹医药：APLD-2304获欧盟CE认证
智通财经 · 08-27
亚虹医药：APLD-2304获欧盟CE认证
每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准
证券之星 · 08-16
每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准
亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%
证券之星 · 08-13
亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%
每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求
证券之星 · 08-09
每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求
亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%
证券之星 · 08-05
亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%
每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元
证券之星 · 07-26
每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元
亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%
证券之星 · 07-23
亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%
加载更多
公司概况
公司名称：
江苏亚虹医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-07
主营业务：
江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域，提供涵盖诊断、治疗、随访等诊疗一体化解决方案。公司的主要产品是APL-1702(希维她)、APL-2302、APL-2501、AT-021、APL-1706(海克威)、APLD-2304、APL-2401、APL-024、APL-1202、APL-1401、APL-2301。
发行价格：
22.98
{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药-U","latestPrice":12.48,"timestamp":1792134000000,"preClose":12.35,"halted":0,"volume":14170501,"delay":0,"changeRate":0.0105,"floatShares":572000000,"shares":572000000,"eps":-0.8612,"marketStatus":"已收盘","change":0.13,"latestTime":"10-16 15:00:00","open":12.49,"high":13.16,"low":12.3,"amount":180000000,"amplitude":0.0696,"askPrice":12.48,"askSize":55,"bidPrice":12.47,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.8612,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792373400000},"marketStatusCode":5,"adr":0,"adjPreClose":12.35,"symbolType":"stock_kcb","openAndCloseTimeList":[[1792114200000,1792121400000],[1792126800000,1792134000000]],"highLimit":13.59,"lowLimit":11.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":572192168,"isCdr":false,"pbRate":5.27,"roa":"--","roe":"--","epsLYR":-0.74,"committee":0.196456,"marketValue":7141000000,"turnoverRate":0.0248,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-20。","afterMarket":{"amount":0,"volume":0,"close":12.48,"buyVolume":0,"sellVolume":0,"time":1792136037746,"indexStatus":"已收盘 10-16 15:30:00","preClose":12.35},"floatMarketCap":7141000000},"requestUrl":"/m/hq/s/688176","defaultTab":"news","newsList":[{"id":"2675308843","title":"亚虹医药（688176）披露2026年员工持股计划草案，10月13日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675308843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675308843?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:33","pubTimestamp":1791884014,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，亚虹医药报收于12.95元，较前一交易日下跌0.38%，最新总市值为74.1亿元。该股当日开盘12.9元，最高13.1元，最低12.46元，成交额达1.67亿元，换手率为2.28%。近日，江苏亚虹医药科技股份有限公司发布《关于召开2026年第一次临时股东会的通知》。股权登记日为2026年10月22日，A股股东均可参会。上述三项议案均为特别决议议案，并对中小投资者单独计票；涉及关联股东需回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300029356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","09939","BK0239","688176","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674670648","title":"亚虹医药（688176）10月9日主力资金净买入936.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674670648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674670648?lang=zh_cn&edition=full","pubTime":"2026-10-10 08:16","pubTimestamp":1791591415,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月9日收盘，亚虹医药报收于13.47元，上涨4.1%，换手率3.52%，成交量20.12万手，成交额2.64亿元。近5日资金流向一览见下表：亚虹医药融资融券信息显示，融资方面，当日融资买入2045.85万元，融资偿还2803.04万元，融资净偿还757.18万元。亚虹医药主营业务：专注于泌尿生殖系统肿瘤及女性健康领域,专注治疗领域集研发、生产和销售为一体的国际领先制药企业,为中国和全球患者提供最佳的诊疗一体化解决方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101000003848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","688176","09939","159938","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673507384","title":"亚虹医药（688176）披露与Theramex签署独家授权许可协议，10月8日股价下跌11.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673507384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673507384?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:41","pubTimestamp":1791452499,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，亚虹医药报收于12.94元，较前一交易日下跌11.37%，最新总市值为74.04亿元。该股当日开盘14.87元，最高15.05元，最低12.83元，成交额达5.39亿元，换手率为7.11%。近日，江苏亚虹医药科技股份有限公司发布《关于与Theramex公司签署有条件的独家授权许可协议的公告》。公告显示，公司与Theramex HQ UK Limited签署有条件的《独家授权许可协议》，Theramex将获得APL-1702在欧洲国家以及澳大利亚、新西兰和土耳其的独家权益，公司保留全球其他区域权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800023160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK1515","BK0239","159938","09939","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673095055","title":"亚虹医药(688176.SH)：与Theramex公司签署独家授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2673095055","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673095055?lang=zh_cn&edition=full","pubTime":"2026-10-07 15:39","pubTimestamp":1791358775,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，近日，公司与Theramex HQ UK Limited(简称“Theramex”)签订有条件的《独家授权许可协议》，根据授权许可协议，Theramex将获得APL-1702(商品名：希维她®/CEVIRA®)在欧洲国家以及澳大利亚、新西兰和土耳其的独家权益。公司保留全球其余区域的相关权益。根据协议，此次交易公司将获得包括1500万美元首付款、1100万美元近期注册里程碑付款，以及商业化里程碑等付款和分级销售提成。交易总金额超过2.5亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","BK1574","159938","BK1515","688176","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671216110","title":"亚虹医药(688176.SH)拟推2026年员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2671216110","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671216110?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:12","pubTimestamp":1790680325,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药 发布2026年员工持股计划(草案)，持股计划经公司股东会审议批准后，将通过非交易过户等法律法规允许的方式取得并持有公司回购专用证券账户所持有的公司股份，合计不超过587.1735万股，约占公司当前股本总额的1.03%。其中拟首次授予476万股，预留111.1735万股。持股计划的存续期为60个月，自公司公告首次授予部分最后一笔标的股票过户至本员工持股计划名下之日起算。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09939","BK0239","159938","BK1574","BK1515","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669404731","title":"亚虹医药（688176）披露APL-2501完成I期临床试验首例受试者入组公告，9月22日股价上涨1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669404731","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669404731?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:06","pubTimestamp":1790085985,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，亚虹医药报收于14.92元，较前一交易日上涨1.29%，最新总市值为85.37亿元。该股当日开盘14.5元，最高15.12元，最低14.45元，成交额达3.81亿元，换手率为4.51%。近日，江苏亚虹医药科技股份有限公司自愿披露关于APL-2501完成I期临床试验首例受试者入组公告。公告显示，公司自主研发的APL-2501在晚期实体瘤患者中开展的I/II期临床试验已完成首例受试者入组。目前该事项对公司近期业绩无重大影响，后续进展存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200041022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688176","09939","159938","BK1574","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669148167","title":"亚虹医药(688176.SH)：APL-2501完成I期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2669148167","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669148167?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:42","pubTimestamp":1790070166,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，近日，公司自主研发的APL-2501(此产品化合物名称为BLB101)在晚期实体瘤患者中开展的I/II期临床试验完成首例受试者入组。APL-2501是公司自主研发的搭载专有亲水性连接子、基于拓扑异构酶抑制剂的抗CLDN6/9抗体药物偶联物(ADC)，预计可以用于治疗包括卵巢癌、非小细胞肺癌、子宫内膜癌、胃癌等多种晚期实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IBBQ","688176","IBBJ","MDTX","PSYK","BK1515","159938","BK0239","BMED","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667568886","title":"每周股票复盘：亚虹医药（688176）将参加科创板业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667568886","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667568886?lang=zh_cn&edition=full","pubTime":"2026-09-13 04:02","pubTimestamp":1789243339,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，亚虹医药报收于12.44元，较上周的13.0元下跌4.31%。本周，亚虹医药9月8日盘中最高价报13.65元。本周关注点公司公告汇总：亚虹医药将于2026年9月16日参加科创板集体业绩说明会，就半年度经营成果与投资者交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300001567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK1574","688176","159938","09939","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581807","title":"亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581807","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666581807?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:33","pubTimestamp":1788946428,"startTime":"0","endTime":"0","summary":"江苏亚虹医药科技股份有限公司近日发布《关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》。公告显示，公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心视频结合网络互动方式召开，会议将就公司2026年半年度经营成果、财务状况等与投资者进行交流。投资者可于2026年9月9日至9月15日16:00前通过上证路演中心网站或公司邮箱提交问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900029739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","688176","BK0239","09939","159938","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663937072","title":"亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663937072","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663937072?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:48","pubTimestamp":1788173298,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，亚虹医药报收于11.86元，较前一交易日下跌0.17%，最新总市值为67.86亿元。近日，江苏亚虹医药科技股份有限公司披露《2026年半年度报告》。本报告期实现营业收入155,353,308.79元，同比增长19.28%；利润总额为-244,770,829.97元；归属于上市公司股东的净利润为-238,604,759.91元；归属于上市公司股东的扣除非经常性损益的净利润为-250,930,825.16元。研发投入占营业收入的比例为127.67%，较上年同期增加38.23个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","09939","BK0239","BK1161","BK1574","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663481270","title":"亚虹医药（688176）2026年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2663481270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663481270?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:15","pubTimestamp":1788041741,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚虹医药发布2026年中报。根据财报显示，亚虹医药增收不增利。本次财报公布的各项数据指标表现一般。财报体检工具显示：建议关注公司现金流状况建议关注财务费用状况建议关注公司应收账款状况持有亚虹医药最多的基金为国联医疗健康混合A，目前规模为0.56亿元，最新净值1.2729，较上一交易日下跌1.3%，近一年上涨19.49%。本文数据来源于亚虹医药2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","09939","BK0239","BK1574","688176","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663485130","title":"每周股票复盘：亚虹医药（688176）Q2收入增21.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663485130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663485130?lang=zh_cn&edition=full","pubTime":"2026-08-30 05:39","pubTimestamp":1788039551,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，亚虹医药报收于11.88元，较上周的12.2元下跌2.62%。本周，亚虹医药8月24日盘中最高价报12.3元。本周关注点来自业绩披露要点：2026年第二季度主营收入8426.74万元，同比上升21.89%。股本股东变化截至2026年6月30日，公司股东户数为2.4万户，较3月31日减少2289.0户，减幅为8.71%。公司发布2026年度“提质增效重回报”行动方案半年度评估报告，上半年实现营业收入15,535.33万元，同比增长19.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","159938","BK1161","688176","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662062740","title":"亚虹医药（688176）披露APLD-2304获得欧盟CE认证，8月28日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662062740","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662062740?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:14","pubTimestamp":1787915646,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，亚虹医药报收于11.88元，较前一交易日下跌0.5%，最新总市值为67.98亿元。该股当日开盘12.08元，最高12.11元，最低11.83元，成交额达7847.04万元，换手率为1.15%。江苏亚虹医药科技股份有限公司于近日披露《自愿披露关于APLD-2304获得欧盟CE认证的公告》。公告显示，公司自主研发的APLD-2304产品近日获得欧盟CE认证及ISO 13485:2016体系认证。此次认证表明公司质量管理体系符合欧盟MDR法规要求，产品可在欧盟及认可该法规的地区销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800044701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK1574","FESXmain","688176","159938","09939","BK0239","FSXEmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662011107","title":"亚虹医药：APLD-2304获欧盟CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2662011107","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662011107?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:27","pubTimestamp":1787830045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176955","title":"每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176955","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176955?lang=zh_cn&edition=full","pubTime":"2026-08-16 03:10","pubTimestamp":1786821019,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，亚虹医药报收于12.98元，较上周的12.81元上涨1.33%。本周，亚虹医药8月13日盘中最高价报13.65元。本周关注点公司公告汇总：APL-2501获FDA同意开展晚期实体瘤临床试验公司公告汇总江苏亚虹医药科技股份有限公司控股子公司Baylink Biosciences Inc收到美国食品药品监督管理局函告，同意其自主研发的APL-2501开展用于治疗晚期实体瘤的临床试验。APL-2501是一种抗CLDN6/9抗体药物偶联物，拟用于多种晚期实体瘤治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","159938","BK0239","BK1161","BK1574","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659391163","title":"亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659391163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659391163?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:31","pubTimestamp":1786631471,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，亚虹医药报收于13.2元，较前一交易日上涨3.29%，最新总市值为75.53亿元。近日，江苏亚虹医药科技股份有限公司控股子公司Baylink Biosciences Inc收到美国食品药品监督管理局函告，同意其自主研发的APL-2501开展用于治疗晚期实体瘤的临床试验。APL-2501是一种抗CLDN6/9抗体药物偶联物，拟用于多种晚期实体瘤治疗。该临床试验申请获批对公司近期业绩无重大影响，药品研发仍存在技术、审批等不确定性风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","09939","BK1574","159938","BK0239","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658200673","title":"每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求","url":"https://stock-news.laohu8.com/highlight/detail?id=2658200673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658200673?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:00","pubTimestamp":1786212048,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，亚虹医药报收于12.81元，较上周的11.36元上涨12.76%。本周，亚虹医药8月7日盘中最高价报12.87元。本周关注点公司公告汇总：亚虹医药及子公司就Photocure仲裁案提起反请求，要求返还660万美元及利息。此前，Photocure因合同纠纷于2026年7月提起仲裁，主张公司未支付全额里程碑款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","159938","BK1161","688176","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657722528","title":"亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657722528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657722528?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:12","pubTimestamp":1785939141,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，亚虹医药报收于12.4元，较前一交易日上涨6.8%，最新总市值为70.95亿元。该股当日开盘11.64元，最高12.49元，最低11.62元，成交额达2.29亿元，换手率为3.29%。近日，江苏亚虹医药科技股份有限公司发布《关于仲裁进展暨提起仲裁反请求的公告》。此前，Photocure因合同纠纷于2026年7月提起仲裁，主张公司未支付全额里程碑款项。公司表示已依约支付相关款项并保留权利，反请求已获受理，但尚未开庭审理，最终影响以仲裁结果为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","09939","BK0239","BK1161","BK1574","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052771","title":"每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052771?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:58","pubTimestamp":1785002293,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，亚虹医药报收于12.58元，较上周的13.03元下跌3.45%。本周，亚虹医药7月22日盘中最高价报14.51元。Photocure请求裁定公司支付剩余440万美元及利息，并承担仲裁费用。目前仲裁已受理，尚未开庭。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","BK1574","BK0239","BK1161","09939","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653295107","title":"亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653295107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653295107?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:35","pubTimestamp":1784817317,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，亚虹医药报收于13.25元，较前一交易日上涨1.14%，最新总市值为75.82亿元。Photocure主张公司应支付因希维她获批而触发的1,100万美元里程碑款，公司已于2026年4月支付660万美元并保留权利，认为未触发全额付款义务。Photocure请求裁定公司支付剩余440万美元及利息，并承担仲裁费用。目前仲裁已受理，尚未开庭。该事项未对公司与Photocure的长期合作及正常经营造成实质性障碍，希维她的生产供应与商业化正有序推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300048226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","BK0239","159938","BK1574","BK1515","688176"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792292885090,"stockEarnings":[{"period":"1week","weight":-0.0735},{"period":"1month","weight":-0.0032},{"period":"3month","weight":-0.0422},{"period":"6month","weight":-0.1009},{"period":"1year","weight":0.2406},{"period":"ytd","weight":0.0843}],"compareEarnings":[{"period":"1week","weight":-0.0256},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0127},{"period":"6month","weight":-0.0827},{"period":"1year","weight":-0.0511},{"period":"ytd","weight":-0.0636}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24001人(较上一季度减少8.71%)","perCapita":"23840股","listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","registeredCapital":"57219万元","survey":" 江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域，提供涵盖诊断、治疗、随访等诊疗一体化解决方案。公司的主要产品是APL-1702(希维她)、APL-2302、APL-2501、AT-021、APL-1706(海克威)、APLD-2304、APL-2401、APL-024、APL-1202、APL-1401、APL-2301。","listedPrice":22.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药-U(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药-U(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药-U,688176,亚虹医药-U股票,亚虹医药-U股票老虎,亚虹医药-U股票老虎国际,亚虹医药-U行情,亚虹医药-U股票行情,亚虹医药-U股价,亚虹医药-U股市,亚虹医药-U股票价格,亚虹医药-U股票交易,亚虹医药-U股票购买,亚虹医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药-U(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药-U(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}